Surround optical-fiber immunoassay

ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Multiple Posters at the 31st Annual European Academy of Dermatology and Venereology (EADV) Congress

Retrieved on: 
Wednesday, September 7, 2022
NASDAQ, Immunoglobulin E, Itch, Sleep, Serum, Congress, POC, TARC, ASLN, GLOBE, Surround optical-fiber immunoassay, European Academy of Allergy and Clinical Immunology, Atopy, Atopic dermatitis, Biomarker, AD, AD1, Patient, LDH, Vaccine, Pharmaceutical industry, Venereology, Dermatology

Three posters are being presented as e-posters throughout the duration of the congress from September 7 to 10, 2022.

Key Points: 
  • Three posters are being presented as e-posters throughout the duration of the congress from September 7 to 10, 2022.
  • Collectively, the data being presented at EADV gives us great confidence to continue investigating eblaskaimabs role in AD and other indications in the future.
  • Signaling through the Type 2 receptor induces expression of a multitude of marker molecules, correlating with disease severity.
  • The poster shows results of patient samples from the proof-of-concept (PoC) trial of eblasakimab in adults with moderate-to-severe atopic dermatitis.

Quidel Receives Amended Emergency Use Authorization for New Sofia® Q Rapid Antigen Test Device

Retrieved on: 
Friday, June 11, 2021
Biotechnology, FDA, Health, Medical devices, Medicine, Branches of biology, Clinical medicine, Medical tests, Immunologic tests, Molecular biology, Clinical Laboratory Improvement Amendments, Healthcare in the United States, Surround optical-fiber immunoassay, COVID-19, Severe acute respiratory syndrome, Quidel Corporation

Sofia Q features a sleek, miniaturized design that reads the same Sofia SARS Antigen FIA tests as Sofia and Sofia 2 - with equal accuracy.

Key Points: 
  • Sofia Q features a sleek, miniaturized design that reads the same Sofia SARS Antigen FIA tests as Sofia and Sofia 2 - with equal accuracy.
  • Sales of Sofia Q device will initially be limited to use with the Sofia SARS Antigen FIA in the CLIA and CLIA-waived professional segments.
  • In addition to the Sofia Q, Quidel offers other rapid diagnostic instrumented systems, including Sofia 2, and Sofia.
  • Quidels Sofia assays for rapid antigen COVID-19 diagnosis include Sofia 2 SARS Antigen FIA and Sofia 2 Flu + SARS Antigen FIA, currently under EUA by the FDA.

Quidel Provides Business Update at 13th Annual Piper Sandler Med-Tech and Diagnostic California Bus Tour; Another SARS Antigen Entrant Does Not Change Quidel’s Strategy

Retrieved on: 
Thursday, August 27, 2020
Professional services, Data management, Health, Medical devices, Infectious diseases, Technology, Finance, Immunologic tests, Branches of biology, Natural sciences, Chemistry, Laboratory techniques, Quidel Corporation, Assay, Surround optical-fiber immunoassay, Lateral flow test, ELISA

Quidel Corporation (NASDAQ: QDEL) (Quidel), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today the following business update in advance of todays presentation and investor meetings at the 13th Annual Piper Sandler Med-Tech and Diagnostic California Bus Tour.

Key Points: 
  • Quidel Corporation (NASDAQ: QDEL) (Quidel), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today the following business update in advance of todays presentation and investor meetings at the 13th Annual Piper Sandler Med-Tech and Diagnostic California Bus Tour.
  • Abbotts entry into the SARS antigen testing market was fully anticipated, as was the potential scale of visually read lateral flow assays.
  • Quidels Sofia has an installed base of over 50,000 Sofia instruments in the United States.
  • Quidel plans to introduce a Sofia Flu + COVID Antigen combination assay, a Sofia Serology assay, and a Solana molecular SARS assay in September.

Quidel’s Sofia® SARS Antigen FIA Updates EUA Performance Data to 96.7% PPA Versus PCR; Product Supports U.S. Initiatives to Expand Access to COVID-19 Testing in Nursing Homes; Receives CE Mark for Use With Sofia® and Sofia® 2 Instruments

Retrieved on: 
Saturday, July 18, 2020
Data management, Health, Technology, Infectious diseases, Software, General Health, Branches of biology, Medicine, Medical specialties, Immune system, Immunologic tests, Pneumonia, Severe acute respiratory syndrome, Zoonoses, McKesson Corporation, Antigen, Stratospheric Observatory for Infrared Astronomy, Surround optical-fiber immunoassay

We expect that this test will continue to play a critical role as an effective first line of defense against COVID-19.

Key Points: 
  • We expect that this test will continue to play a critical role as an effective first line of defense against COVID-19.
  • Healthcare professionals can purchase the Sofia SARS Antigen FIA in the United States through distribution representatives for Cardinal Health, Fisher Healthcare, Henry Schein, McKesson, or Medline.
  • Separately, the Sofia SARS Antigen FIA received CE Mark for use with the Sofia and Sofia 2 instruments.
  • The CE Mark allows Quidel to market and sell the Sofia SARS Antigen FIA in Europe, as well as other countries that accept the CE Mark.

Quidel Announces Preliminary Revenue for Second Quarter 2020

Retrieved on: 
Monday, July 6, 2020
Technology, Medical devices, Genetics, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Data management, Medicine, Branches of biology, Immunologic tests, Clinical medicine, Medical tests, Biochemistry methods, Biotechnology, Immunoassay, Surround optical-fiber immunoassay, Severe acute respiratory syndrome, Molecular diagnostics

Our second quarter was even stronger than we had expected, driven by demand for our COVID-19 Molecular Diagnostics and Rapid Immunoassay products.

Key Points: 
  • Our second quarter was even stronger than we had expected, driven by demand for our COVID-19 Molecular Diagnostics and Rapid Immunoassay products.
  • Later in the quarter, we completed the development of Sofia SARS Antigen, gained EUA clearance, and manufactured almost 4 million Sofia SARS Antigen cassettes in the quarter.
  • These preliminary results are based on managements initial analysis of operations for the quarter ended June 30, 2020.
  • The company expects to issue full financial results for the second quarter in late July.

Quidel Receives BARDA Funding to Develop Point-of-Care Diagnostic Assay That Includes COVID-19

Retrieved on: 
Thursday, June 11, 2020
Medical Supplies, Biotechnology, White House, Federal Government, Health, General Health, Pharmaceutical, Research, Infectious diseases, Genetics, Public policy, Government, Science, Branches of biology, Natural sciences, Laboratory techniques, Chemistry, Medical tests, Emergency Use Authorization, Food and Drug Administration, Surround optical-fiber immunoassay, Assay, Quidel Corporation, Quidel Corporation, the project

The next-generation Sofia 2 system also comes connected to Virena, Quidels data management system, which provides aggregated, de-identified testing data in near real-time.

Key Points: 
  • The next-generation Sofia 2 system also comes connected to Virena, Quidels data management system, which provides aggregated, de-identified testing data in near real-time.
  • BARDA funding will directly support Quidels development of the four-virus, point-of-care test.
  • The goal of the funding is to achieve an Emergency Use Authorization (EUA) for the test by the U.S. Food and Drug Administration (FDA) within the funding period.
  • Quidel currently sells several Sofia assays in the United States, including the Sofia SARS Antigen FIA under FDA EUA.

Quidel Receives Emergency Authorization for Rapid Antigen COVID-19 Diagnostic Assay

Retrieved on: 
Saturday, May 9, 2020
Infectious diseases, FDA, Health, Medical Supplies, Branches of biology, Medical specialties, Medicine, Bacterial diseases, Laboratory techniques, Industrial hygiene, Gram-negative bacteria, Pathogenic bacteria, McKesson Corporation, Legionella, Surround optical-fiber immunoassay, Assay

The next-generation Sofia 2 system also comes connected to Virena, Quidels data management system, which provides aggregated, de-identified testing data in near real-time.

Key Points: 
  • The next-generation Sofia 2 system also comes connected to Virena, Quidels data management system, which provides aggregated, de-identified testing data in near real-time.
  • The assay is currently available for sale in the United States under EUA, and Quidel is now shipping the product to its customers.
  • In addition, Quidel also markets Sofia tests for Lyme Disease, Legionella and S. pneumoniae in Europe.
  • Healthcare professionals can purchase the Sofia 2 SARS Antigen FIA through distribution representatives for Cardinal Health, Fisher Healthcare, Henry Schein, or McKesson.

When Prions are Personal

Retrieved on: 
Monday, October 21, 2019
Branches of biology, Biology, Amyloidosis, Transmissible spongiform encephalopathies, Prions, Genetics, Proteins, PRNP, Neurodegeneration, Surround optical-fiber immunoassay, Protein misfolding cyclic amplification

Almost everyone produces the prion protein, known as PrP for short, which is found in the brain and cerebrospinal fluid.

Key Points: 
  • Almost everyone produces the prion protein, known as PrP for short, which is found in the brain and cerebrospinal fluid.
  • For husband-and-wife team Sonia Vallabh and Eric Vallabh Minikel, prions became personal when Vallabh's mother died of a mysterious, rapidly-advancing neurodegenerative disease.
  • Some early trials in mice give Minikel hope, he said: mice infected with prions, if treated before they show symptoms, survive longer without disease.
  • The Society publishes three journals: the Journal of Biological Chemistry, the Journal of Lipid Research, and Molecular and Cellular Proteomics.